Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21583996 | 0.93 | MAP3K5 (0.39) | PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL1485090 | 0.89 | PIK3CA (0.54) | PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL19594359 | 0.85 | PIK3CA (0.43) | PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL1485608 | 0.84 | MAP3K5 (0.39) | PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL1485023 | 0.81 | PIK3CA (0.40) | PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL12538834 | 0.80 | MAP3K14 (0.42) | PIK3CD | |
| SCHEMBL12539133 | 0.80 | PIK3CD (0.40) | PIK3CAPIK3CD | |
| SCHEMBL1485015 | 0.80 | MAP3K14 (0.44) | PIK3CAPIK3CGPIK3CD | |
| SCHEMBL15490518 | 0.80 | MAP3K14 (0.40) | PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL12689129 | 0.79 | PIK3CA (0.49) | PIK3CAPIK3CGPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| US-12624050-B2 | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| EP-4696380-A2 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20250326745-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4585597-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2025-07-16 | — | — | EP | disclosed |
| US-20250197386-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-06-19 | — | — | US | disclosed |
| CN-111909173-B | Benzoxazepine oxazolidinone compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-4212536-B1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2025-02-19 | — | — | EP | disclosed |
| EP-3805231-B1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN) | 2024-10-16 | — | — | EP | disclosed |
| CN-113227101-B | Salt or crystal form containing tricyclic derivative and pharmaceutical composition thereof | 上海翰森生物医药科技有限公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20120245144-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | GENENTECH, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245144-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | GENENTECH, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245144-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | GENENTECH, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-8242104-B2 | Benzoxazepin P13K inhibitor compounds and methods of use | F. HOFFMAN-LA ROCHE AG (CH) | 2012-08-14 | — | — | US | disclosed |
| EP-2483278-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011036280-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011036280-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245144-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | PIK3CA, PIK3CD, PIK3R4 | PIK3CA 1/4885PIK3CG 5/4885PIK3CD 2/4885 |
| US-12624050-B2 | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof | OGDH, ME1, GCDH | PIK3CA 91/4885PIK3CG 217/4885PIK3CD 196/4885 |
| US-20250326745-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PDPK1 | PIK3CA 1/4885PIK3CG 8/4885PIK3CD 2/4885 |
| US-20250197386-A1 | BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PDPK1 | PIK3CA 1/4885PIK3CG 8/4885PIK3CD 2/4885 |
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | PIK3CA, PIK3R1, PIK3CD | PIK3CA 1/4885PIK3CG 15/4885PIK3CD 3/4885 |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | PIK3CA 2/4885PIK3CG 23/4885PIK3CD 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.